Jun. 4 at 1:34 PM
$MDCX : Tiny
$18M Market Cap Targeting Multi Billion Dollar Markets!🚨
Medicus Pharma is quietly building a biotech pipeline focused on massive unmet markets in skin cancer and prostate/urology treatments through its proprietary SkinJect and Teverelix programs.
Highlights:
🔥 Estimated cash runway now 24+ months
🔥 Positive Phase 2 SkinJect data showed registrational-grade clearance rates
🔥 FDA-cleared advancement for Teverelix Phase 2b study
🔥 Filed Orphan Drug application for SkinJect in Gorlin Syndrome
Upcoming Catalysts:
✔️ More SkinJect clinical data
✔️ FDA/regulatory milestones
✔️ Potential partnerships/licensing deals
✔️ Teverelix Phase 2b progression
Despite having a market cap of only around
$18M, MDCX is pursuing potential multi billion dollar opportunities in markets projected to exceed
$12B combined, including skin cancer, which impacts more than 5 million Americans each year.
Communicated Disclaimer: http://stockresearchtoday.com/mdcx/
Sector peers:
$CERO $MCRB $TCON $ABEO